AIM IMMUNOTECH INC. Gain (Loss) on Fair Value Hedge Ineffectiveness, Net
AIM IMMUNOTECH INC. (AIM) reported Gain (Loss) on Fair Value Hedge Ineffectiveness, Net of $1.80 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnFairValueHedgeIneffectivenessNet · last filed 2023-03-31
- AIM IMMUNOTECH INC. gain (loss) on fair value hedge ineffectiveness, net for fiscal 2021 was $1.80M.
| Period end | Gain (Loss) on Fair Value Hedge Ineffectiveness, Net 12 month |
|---|---|
| 2021-12-31 | $1.80M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |